How long does it take for cabozantinib to be effective? Interpretation of treatment response cycle

Cabozantinib is an oral multi-target tyrosine kinase inhibitor that mainly acts on multiple signaling pathways such as MET, VEGFR, RET and so on. It is widely used to treat solid tumors such as renal cell carcinoma, hepatocellular carcinoma and medullary thyroid carcinoma. In clinical applications, patients are usually concerned about how long it will take to see the therapeutic effect after taking this drug, which is closely related to the individual's condition, tumor type and medication compliance.

Generally speaking, some patients may initially feel changes in their condition within 4 to 8 weeks after taking the medicine, such as pain relief, improvement in physical strength, or relief of tumor-related symptoms. However, to evaluate its actual anti-tumor effect, such as tumor volume reduction, disease control, etc., it is usually necessary to conduct the 1 re-examination imaging evaluation, which is usually scheduled around 8To12 weeks, that is, after 2 to 3 courses of treatment. At this stage, CT or MRI can be used to determine whether the tumor is stable, shrinking, or progressing.

It is worth noting that the effect of targeted drugs is often "controlling", with the goal of delaying disease progression and stabilizing lesions, rather than eliminating tumors immediately, so some patients may not feel significant improvement in the early stages. Doctors usually make comprehensive judgments based on tumor markers, imaging results, and clinical manifestations, rather than relying solely on the patient's subjective feelings.

In addition, the effectiveness of the drug is also affected by factors such as regular medication use and timely treatment of adverse reactions. If the patient experiences severe side effects and interrupts treatment, the efficacy may be affected. In short, the efficacy of cabozantinib usually requires regular medication for at least 2 to 3 months before it can be objectively evaluated. It is recommended that patients remain patient in the early stages of treatment, follow up regularly, and continue to adjust the treatment plan under the guidance of a doctor.

Reference materials:https://www.drugs.com